Novo Nordisk
-
healthFrance Becomes First EU Country to Reimburse Weight-Loss Drugs
France will start covering costs of Wegovy and Mounjaro from June 15, a historic move making it the first EU nation to offer permanent reimbursement for GLP-1 weight-loss medications.
-
healthNovo Nordisk Cuts Ozempic Price in Canada to Compete with Generics
Novo Nordisk reduces Ozempic cost for uninsured Canadians as generic semaglutide enters the market, slashing prices by roughly a third.
-
healthPeptide Craze Surges Beyond GLP-1s as FDA Faces Pressure to Ease Access
The peptide market is exploding amid regulatory tensions, with the FDA set to consider loosening restrictions on several peptides this summer.
-
healthGlobal Obesity Crisis Widens as Treatment Access Lags in Hardest-Hit Regions
New research reveals obesity rates are accelerating in developing nations while GLP-1 drugs remain concentrated in wealthier countries, highlighting a critical equity gap.
-
healthOzempic Breath: The Unsettling Keto-Like Side Effect Patients Are Reporting
Patients taking GLP-1 drugs report 'fishy' bad breath known as Ozempic breath. Experts discuss dehydration as the likely cause.
-
healthFDA Targets Copycat Weight-Loss Drugs, Limits Bulk Production
The FDA proposes removing Novo Nordisk and Eli Lilly's weight-loss drugs from a compounding list to curb unauthorized bulk production.
-
healthUS Prescription Drug Spending on Track to Exceed $1 Trillion, Fueled by GLP-1s
U.S. drug spending hit $915B in 2025, set to top $1T in 2026, driven by GLP-1 weight-loss drug demand. Eli Lilly and Novo Nordisk dominate the market.
-
healthOral Semaglutide Shows Efficacy in Pediatric Type 2 Diabetes Trial
Phase 3 PIONEER TEENS trial demonstrates oral semaglutide's potential as a first-in-class treatment for adolescents with type 2 diabetes.